Vaccine candidate against COVID-19
LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.[ 1] [ 2] [ 3] [ 4]
It was found to be safe and well tolerated.[ 5]
^ "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial" . chictr.org.cn . Chinese Clinical Trial Registry. Retrieved 15 October 2021 .
^ "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001" . ClinicalTrials.gov . 18 November 2021. NCT05125926. Retrieved 18 November 2021 .
^ "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial" . chictr.org.cn . Chinese Clinical Trial Registry. Retrieved 15 October 2021 .
^ "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001" . ClinicalTrials.gov . 30 November 2021. NCT05137444. Retrieved 30 November 2021 .
^ Tang R, Zeng Y, Zhou Y, Liang Q, Kang W, Yang Z, et al. (2 May 2024). "Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study". Expert Review of Vaccines . 23 (1): 498–509. doi :10.1080/14760584.2024.2337051 . PMID 38695310 .